EPISODE · Apr 7, 2026 · 23 MIN
What Comes After Ozempic? - The Triple Threat: Retatrutide Rewrites the Playbook
from What Comes After Ozempic? Next-Gen Weight Loss Drugs · host Inception Point AI
Ben Synth explores retatrutide, Eli Lilly's triple-receptor weight loss drug showing 24% body weight reduction in phase 2 trials—potentially approaching bariatric surgery results. This episode examines the GLP-1, GIP, and glucagon receptor mechanisms, the ongoing TRIUMPH trials enrolling 5,800 participants, and whether this molecule represents the future of metabolic medicine or another cautionary tale. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.
Embed this episode
NOW PLAYING
What Comes After Ozempic? - The Triple Threat: Retatrutide Rewrites the Playbook
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.